Lhermitte-Duclos Disease
Symptoms, Doctors, Treatments, Advances & More

Save information for later
Sign Up

Learn About Lhermitte-Duclos Disease

What is the definition of Lhermitte-Duclos Disease?
Lhermitte-Duclos disease (LDD) is a very rare, benign (non-cancerous) brain tumor, called a dysplastic gangliocytoma of the cerebellum, that is characterized by abnormal development and enlargement of the cerebellum, and an increased intracranial pressure. LDD manifests most commonly in the third and fourth decades of life. Symptoms may include headache, nausea, cerebellar dysfunction, hydrocephalus, ataxia (problems with movement and coordination), and visual disturbances. Other features may include an enlarged brain (megalencephaly), hydromyelia, extra fingers or toes (polydactyly), partial gigantism, and/or a large tongue (macroglossia). Lhermitte-Duclos disease can occur as an isolated condition; it is also associated with a hereditary cancer syndrome called Cowden disease. Although the exact cause is unknown, genetic changes in the PTEN gene have been identified in some individuals with LDD.
What are the alternative names for Lhermitte-Duclos Disease?
  • Lhermitte-Duclos disease
  • Dysplastic gangliocytoma of the cerebellum
Who are the top Lhermitte-Duclos Disease Local Doctors?
Elite in Lhermitte-Duclos Disease
Elite in Lhermitte-Duclos Disease
Referral may be required
Nijmegen, GE, NL 

Nicoline Hoogerbrugge practices practicing medicine in Nijmegen, Netherlands. Ms. Hoogerbrugge is rated as an Elite expert by MediFind in the treatment of Lhermitte-Duclos Disease. She is also highly rated in 22 other conditions, according to our data. Her clinical expertise encompasses Lhermitte-Duclos Disease, Bannayan-Riley-Ruvalcaba Syndrome, Cowden Syndrome, Salpingo-Oophorectomy, and Oophorectomy.

Elite in Lhermitte-Duclos Disease
Elite in Lhermitte-Duclos Disease
Referral may be required
Nijmegen, GE, NL 

Linda Hendricks practices practicing medicine in Nijmegen, Netherlands. Ms. Hendricks is rated as an Elite expert by MediFind in the treatment of Lhermitte-Duclos Disease. She is also highly rated in 6 other conditions, according to our data. Her clinical expertise encompasses Cowden Syndrome, Bannayan-Riley-Ruvalcaba Syndrome, Lhermitte-Duclos Disease, and Ruvalcaba Syndrome.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Lhermitte-Duclos Disease
Elite in Lhermitte-Duclos Disease
Referral may be required
Nijmegen, GE, NL 

Janneke Hoeijmakers-Schuurs practices practicing medicine in Nijmegen, Netherlands. Hoeijmakers-Schuurs is rated as an Elite expert by MediFind in the treatment of Lhermitte-Duclos Disease. They are also highly rated in 6 other conditions, according to our data. Their clinical expertise encompasses Cowden Syndrome, Bannayan-Riley-Ruvalcaba Syndrome, Lhermitte-Duclos Disease, and Ruvalcaba Syndrome.

What are the latest Lhermitte-Duclos Disease Clinical Trials?
Genotype-phenotype Correlations of Pediatric Patients With PTEN Hamartoma Tumor Syndrome (PHTS) and Creation of Patient Registry

Summary: PtenTurkiye.org' is a national ( Turkish), web-based registry for PTEN Hamartoma Tumour ( PHTS) syndrome established in 2022. It is designed to increase awareness, gather scientific knowledge by collaboration and increase data accessibility, collect high-quality data on the epidemiology, genetic background and natural history of PHTS especially for pediatric patients so that more accurate follow u...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Familial Investigations of Childhood Cancer Predisposition

Summary: NOTE: This is a research study and is not meant to be a substitute for clinical genetic testing. Families may never receive results from the study or may receive results many years from the time they enroll. If you are interested in clinical testing please consider seeing a local genetic counselor or other genetics professional. If you have already had clinical genetic testing and meet eligibility...

Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center